Prostate Cancer Canada Releases New Recommendations
New recommendations released today by Prostate Cancer Canada
(PCC) will empower Canadian males to take a more active role in monitoring their number one cancer risk: prostate cancer. A recent nationwide poll showed that while 87% of Canadian men aged 35+ fear prostate cancer, less than half anticipate being tested in the next 12 months – even though early diagnosis can increase the odds of survival.
“Prostate Cancer Canada recognizes that men need to be better informed about prostate testing, particularly the Prostate Specific Antigen (PSA) blood test,” says Dr. Stuart Edmonds, VP, Research, Health Promotion & Survivorship, Prostate Cancer Canada. “To address this confusion, we conducted an extensive review of the evidence and from this developed our primary recommendation: Men should get a baseline PSA test in their 40s instead of waiting until their 50s.”
“PSA levels can vary between individuals so a test in the early 40’s can provide a baseline and allow us to better tailor clinical follow-up,” says Prostate Cancer Canada spokesperson Dr. Rajiv Singal, Urologist at Toronto East General Hospital and Assistant Professor at the University of Toronto. “The PSA is an important marker for a disease in which symptoms are not always present.”
PCC also recommends the decision to end PSA testing should be based on individual risk, rather than an arbitrary cut-off such as age 70. “Men are living longer and their lives should not be cut short or diminished by prostate cancer,” says Dr. Edmonds. “The decision to end testing should be a shared decision determined by a man and his primary care provider.”
“Some men are at increased risk because of ethnicity (Black African or Black Caribbean descent), a family history of prostate cancer, or age,” says Dr. Singal. “Men at high risk should talk to their primary care provider even earlier than their 40s. However, in my 18 years of practice, the majority of aggressive cancers have been found in men with seemingly no risk factors – underscoring the importance of baseline testing.”
Canadian men are fearful and uncertain about what to do
Prostate Cancer Canada’s recommendations will help to relieve confusion, uncertainty and fear among Canadian men. An online poll conducted for Prostate Cancer Canada among men aged 18+ found over half (55%) either didn’t know or under-estimated a man’s lifetime risk of developing prostate cancer.
Only 16% of respondents were able to correctly identify that a man’s lifetime risk of prostate cancer is 1 in 7.
Almost half (44%) of men admitted being reluctant to be tested for prostate cancer. Also concerning to Prostate Cancer Canada is that three-quarters of men (74%) assumed that a positive test result inevitably leads to treatment. PSA testing is primarily a means of monitoring prostate health. One abnormal test result does not mean leaping into treatment.
“We released our recommendations because we believe it is critical for men to initiate these important discussions with their healthcare providers,” says Rocco Rossi, CEO of Prostate Cancer Canada. “Untreated and late-stage prostate cancer can have devastating physical and psychosocial effects and men need to become informed healthcare consumers and their own healthcare advocates.”
“Given the monitoring and treatment options available, it is inexcusable that prostate cancer should be missed or ignored,” adds Dr. Singal. “We fully appreciate that men may be fearful of the process – but without a quick check, we can’t know what are dealing with. It is critical to their health and well-being that Canadian men be aware, talk to their doctors and get tested.”
Prostate cancer is the most common cancer to affect Canadian men, impacting one in seven men over the course of their lifetime. Prostate Cancer Canada funds critical programs related to awareness and public education, advocacy, support of those affected, and research into the prevention, detection, treatment and cure of prostate cancer. For more information visit prostatecancer.ca
and follow us on Twitter
Link to b-roll: http://cnw.pathfireondemand.com/viewpackage.action?packageid=732
For more information:
Prostate Cancer Canada
416-441-2131 ext. 239